Product Images Kanjinti
View Photos of Packaging, Labels & Appearance
- Figure 1Studies 1 and 2: Cumulative Incidence of Time to First LVEF Decline of ≥ 10 Percentage Points from Baseline and to Below 50% with Death as a Competing Risk Event - kanjinti 01
- Figure 2Study 3: Cumulative Incidence of Time to First LVEF Decline of ≥ 10 Percentage Points from Baseline and to Below 50% with Death as a Competing Risk Event - kanjinti 02
- Figure 3Study 4: Cumulative Incidence of Time to First LVEF Decline of ≥10 Percentage Points from Baseline and to Below 50% with Death as a Competing Risk Event - kanjinti 03
- Figure 4Duration of Disease Free Survival in Patients with Adjuvant Treatment of Breast Cancer (Studies 1 and 2) - kanjinti 04
- Figure 5Duration of Overall Survival in Patients with Adjuvant Treatment of Breast Cancer (Studies 1 and 2) - kanjinti 05
- Figure 6Duration of Disease Free Survival in Patients with Adjuvant Treatment of Breast Cancer (Study 4) - kanjinti 06
- Figure 7Updated Overall Survival in Patients with Metastatic Gastric Cancer (Study 7) - kanjinti 07
- PRINCIPAL DISPLAY PANELNDC 55513-132-01KANJINTI™(trastuzumab anns)For Injection420 mg/vialFor intravenous infusion after reconstitution420 mg/vialContents:Each carton contains one 420 mg KANJINTI multiple-dose vial.AMGEN® Store vial in the original carton to protect from light in the refrigerator at2°C to 8°C (36° F to 46°F) until time of reconstitution.Do not shake. Do not freeze reconstituted solution. - kanjinti 09
- kanjinti 0a
Product Label Images
The following 9 images provide visual information about the product associated with Kanjinti NDC 55513-164 by Amgen, Inc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Figure 1Studies 1 and 2: Cumulative Incidence of Time to First LVEF Decline of ≥ 10 Percentage Points from Baseline and to Below 50% with Death as a Competing Risk Event - kanjinti 01
Figure 2Study 3: Cumulative Incidence of Time to First LVEF Decline of ≥ 10 Percentage Points from Baseline and to Below 50% with Death as a Competing Risk Event - kanjinti 02
This appears to be a chart displaying cumulative incidence rates, with observations at various time intervals after randomization. The chart also includes the number at risk for each interval, as well as data regarding the drug Trastuzuma for a one-year time period. Some of the numbers are unreadable, making it difficult to fully interpret the information.*
Figure 3Study 4: Cumulative Incidence of Time to First LVEF Decline of ≥10 Percentage Points from Baseline and to Below 50% with Death as a Competing Risk Event - kanjinti 03
Figure 4Duration of Disease Free Survival in Patients with Adjuvant Treatment of Breast Cancer (Studies 1 and 2) - kanjinti 04
Figure 5Duration of Overall Survival in Patients with Adjuvant Treatment of Breast Cancer (Studies 1 and 2) - kanjinti 05
Figure 6Duration of Disease Free Survival in Patients with Adjuvant Treatment of Breast Cancer (Study 4) - kanjinti 06
Figure 7Updated Overall Survival in Patients with Metastatic Gastric Cancer (Study 7) - kanjinti 07
This is a survival probability table for a treatment that involves Fluoropyrimidine and Cisplatin. The table shows the number of patients who survived for a certain duration (in months) after treatment. The treatment involves two options: Fluoropyrimidine + Cisplatin and Fluoropyrimidine + Cisplatin + Trastuzumab. The number of patients who survived for each duration is given in the table. The treatment duration ranges from 0 to 50 months. There is some unreadable text in the second row.*
PRINCIPAL DISPLAY PANELNDC 55513-132-01KANJINTI™(trastuzumab anns)For Injection420 mg/vialFor intravenous infusion after reconstitution420 mg/vialContents:Each carton contains one 420 mg KANJINTI multiple-dose vial.AMGEN® Store vial in the original carton to protect from light in the refrigerator at2°C to 8°C (36° F to 46°F) until time of reconstitution.Do not shake. Do not freeze reconstituted solution. - kanjinti 09
KANJINTI is a medication used for intravenous infusion after reconstruction. It is stored in its original carton to protect it from light in the refrigerator at a temperature of 2°C to 8°C until the time of reconstruction. The text provides details regarding the contents and dosage of KANJINTI.*
kanjinti 0a
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
